ArticleMedComm2024

Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.

Zhonghan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.